Pharmacotherapeutic group: Sex hormones and modulators of the genital system, progestogens, ATC code: G03DA04.
Mechanism of action
Progesterone is a natural endogenous hormone of the corpus luteum and is the most important hormone of the corpus luteum and the placenta. It acts on the endometrium by converting the proliferating phase to the secretory phase. Prometrium 400mg soft vaginal capsules has all the properties of endogenous progesterone with induction of a full secretory endometrium and in particular has a gestagenic, antiestrogenic, slightly anti-androgenic and antialdosterone effects.
The pharmacodynamic effects for threatened and recurrent miscarriage are that progesterone modulates maternal immune responses to protect the foetus, improves the utero-placental circulation, maintains cervical integrity throughout pregnancy, promotes myometrial relaxation, inhibits prostaglandin production, and possesses anti-inflammatory properties.
Clinical efficacy/safety studies
The efficacy and safety of micronized progesterone in preventing miscarriage in women, with dual risk factors of early pregnancy bleeding and previous history of miscarriages, was evaluated in the PRISM study. The benefit of treatment with vaginal progesterone 400 mg twice daily increased with an increasing number of prior miscarriages. The benefit reached statistical significance in the prespecified subgroup of women with three or more previous miscarriages and current pregnancy bleeding; live birth rate was 72% (98/137) with progesterone vs 57% (85/148) with placebo (rate difference 15%; risk ratio, 1.28, 95% CI, 1.08-1.51; P=.004). For this group, the number needed to treat was 8 (95% CI, 7-10). From a safety perspective, progesterone 400 mg was well tolerated.